購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
B6-hB7-H4 (hVTCN1) Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
B6-hB7-H4 (hVTCN1) Mouse
製品名
B6-hB7-H4 (hVTCN1) Mouse
製品ID
C001806
系統名
C57BL/6NCya-Vtcn1tm1(hVTCN1)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「B6-hB7-H4 (hVTCN1) Mouse(カタログ番号C001806)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
基本情報
関連リソース
基本情報
遺伝子名
遺伝子別名
B7X, B7H4, B7S1, B7-H4, B7h.5, VCTN1, PRO1291
NCBI ID
染色体
Chr 1
MGI ID
さらに
系統詳細
The VTCN1 gene, also known as B7-H4, B7S1, or B7x, encodes a protein belonging to the B7 costimulatory protein family, which is typically found on the surface of antigen-presenting cells. This protein functions as a negative regulator of T-cell-mediated immune responses by inhibiting T-cell activation, proliferation, cytokine production, and cytotoxicity, playing a crucial role in maintaining immune homeostasis, particularly in the tumor microenvironment [1]. While VTCN1 mRNA can be detected in various lymphoid and non-lymphoid tissues such as kidney, pancreas, liver, lung, ovary, placenta, spleen, and testis, its protein expression is often restricted in normal tissues, with notable expression on activated T- and B-cells, monocytes, and dendritic cells [2]. However, it is frequently overexpressed on the cell surface of various cancer cells and tumor-associated macrophages, where it contributes to immune escape. Associated diseases primarily include a wide range of cancers, such as breast, ovarian, endometrial, renal cell, non-small cell lung, pancreatic, and colorectal cancers, where high levels correlate with tumor progression and poor prognosis [3]. Furthermore, dysregulation of VTCN1 has also been linked to autoimmune and inflammatory diseases like rheumatoid arthritis and type 1 diabetes [4].
The B6-hB7-H4 (hVTCN1) mouse is a humanized model, constructed by replacing the partial extracellular domain of the endogenous mouse Vtcn1 gene with the partial extracellular domain of the human VTCN1 gene. B6-hB7-H4 (hVTCN1) mice can be used for research into the pathogenesis of various cancers, as well as autoimmune and inflammatory diseases. They are also useful for the screening, development, and safety evaluation of VTCN1-targeted drugs.
参考文献
John P, Wei Y, Liu W, Du M, Guan F, Zang X. The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial. Trends Pharmacol Sci. 2019 Nov;40(11):883-896.
Dawidowicz M, Kot A, Mielcarska S, Psykała K, Kula A, Waniczek D, Świętochowska E. B7H4 Role in Solid Cancers: A Review of the Literature. Cancers (Basel). 2024 Jul 11;16(14):2519.
Zhou L, Duan Y, Fu K, Zhang M, Li K, Yin R. The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives. Front Immunol. 2024 Aug 29;15:1426050.
Vaishnav J, Khan F, Yadav M, Parmar N, Buch H, Jadeja SD, Dwivedi M, Begum R. V-set domain containing T-cell activation inhibitor-1 (VTCN1): A potential target for the treatment of autoimmune diseases. Immunobiology. 2022 Nov;227(6):152274.
系統作製戦略

Figure 1. Gene editing strategy of B6-hB7-H4 (hVTCN1) Mice. The mouse Vtcn1 endogenous partial extracellular domain will be replaced with the human VTCN1 partial extracellular domain.
適用分野
VTCN1-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of certain cancers;
Research on the pathological mechanisms and therapeutic approaches of autoimmune and inflammatory diseases like rheumatoid arthritis (RA) and type 1 diabetes.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
